40 likes | 209 Views
Supplementary Figure S1. A. A375. A375R2. Vemurafenib (µM). 0. 0.1. 1. 10. 0. 0.1. 1. 10. BRAF (Full Length). p61-BRAF Isoform. pMEK. pERK. B. Tubulin. A375. A375-R4 NRas Q61K. Vemurafenib (µM). Tubulin. Ras. pS338-cRaf. pMEK. pERK. Supplementary Figure S2.
E N D
Supplementary Figure S1 A A375 A375R2 Vemurafenib (µM) 0 0.1 1 10 0 0.1 1 10 BRAF (Full Length) p61-BRAF Isoform pMEK pERK B Tubulin A375 A375-R4 NRas Q61K Vemurafenib (µM) Tubulin Ras pS338-cRaf pMEK pERK
Supplementary Figure S2 Vemurafenib Vehicle Vemurafenib LY2835219
Supplementary Figure S3 A375 A375-RV2 Vemurafenib (µM) pERK Tubulin
Supplementary Figure S4 A %G1= 54.25 %S = 34.96 %G2/M = 10.79 %G1= 82.10 %S = 2.73 %G2/M = 15.17 %G1= 74.95 %S = 3.81 %G2/M = 21.24 M14 300 %G1= 58.58 %S = 24.88 %G2/M = 16.54 250 A375-R1 200 M14-R M14-R Relative Caspase 3 Activity (%) 150 100 M14 A375 DMSO 1.5mM 5mM 50 LY2835219 B 0 %G1= 38.71 %S = 35.28 %G2/M = 26.02 0.0 2.6 %G1= 55.23 %S = 13.34 %G2/M = 31.43 3.0 3.5 4.0 Log Concentration LY2835219 (nM) %Debris = 72.17 %Debris = 41.73 A375-RV1 A375-RV2 A375-RV1 A375-RV2 A375-R1 A375-R1 C A375 A375 Cyclin D1 ←Cyclin D2 Cleaved-PARP Tubulin Cyclin D1 siRNA